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Background: Recent studies have revealed an inverse epidemiological correlation between Alzheimer’s disease
(AD) and cancer − patients with AD show a reduced risk of cancer, while cancer survivors are less likely to develop AD.
These late discoveries in human subjects call for explorative studies to unlock the underlying biological mechanism,
but also may shed new light on conceptual interrogation of the principal pathogenic players in AD etiology.
Discussion: Here we hypothesize that this negative correlation reflects a rebalance of biosynthetic propensity
between body systems under the two disease statuses. In normal condition the body cellular systems are maintained
homeostatically under a balanced cell degenerative vs. surviving/regenerative propensities, determined by biosynthetic
resources for anabolic processing. AD pathogenesis involves neurodegeneration but also aberrant regenerative, or
reactive anabolic, burden, while cancer development is driving by uncontrolled proliferation inherent with excessive
anabolic activity. The aberrant neural regenerative propensity in AD pathogenesis and the uncontrolled cellular
proliferative propensity in cancer pathogeneses can manifest as competitive processes, which could result in the
inverse epidemiological correlation seen among the elderly.
Summary: The reduced prevalence of AD in cancer survivors may implicate a strong impact of aberrant neural
regenerative burden in neurodegeneration. Further explorative studies into the inverse correlation between AD and
cancer should include examinations of the proliferative propensity of tumor cells in AD models, and the development
of AD-like neuropathology in cancer models as well as following anti-proliferative drug treatment.
Keywords: Aberrant neuroplasticity, Cell cycle activation, Neurodegeneration, TumorogenesisBackground
Alzheimer’s disease (AD) and cancer are major risk
factors threatening human health and life especially in
the elderly. AD is an age-dependent neurodegenerative
disease, while the incidence of cancer is also dramatically
increased with age. With the global population aging, AD
and cancer become the leading causes of death in most
societies across the globe [1,2]. A number of recent studies
have revealed a novel inverse correlation in the prevalence
of AD vs. cancer in multiple ethnic groups [3-11]. Such a
phenomenon points to a certain biological/pathogenic
interaction, likely some type of competitive cellular pro-
cess, between the two disease conditions. Decoding this* Correspondence: yanxiaoxin@csu.edu.cn
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unless otherwise stated.phenomenon may allow a better understanding of the
governing pathogenic factors for AD and/or cancer, and
could be also informative for the development of new
therapeutical strategies for these diseases. Accordingly, it
is of medical relevance to formulate hypothetical model(s)
to facilitate mechanistic investigation into the AD/cancer
relationship. AD and cancer are both complex condi-
tions with numerous molecular and signaling anomalies
occurring in multiple body systems. At the present, little
information about the molecular links between the two
conditions can be drawn from the human studies. None-
theless, to understand the inverse correlation it can be
benefited from an analysis of the major pathogenic
features of the two disease conditions in reference to
some basic cell biology principle(s). In this article we
first review recent literature documenting the negative
association between AD and cancer in human population-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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features of AD, with an emphasis on the coexistence of
neurodegenerative and aberrant regenerative propensities
in the brain. We then discuss the basic aspect of cancer
biology, focusing on the influence on body tissue sys-
tems by uncontrolled cell proliferation in tumorogenesis.
Finally we hypothesize that the reduced AD vs. cancer
comorbidity in the elderly may be considered as a result of
rebalance of biosynthetic kinetics between body systems.
Overall, the inverse epidemiological correlation between
AD and cancer may implicate a strong impact of the
aberrant neural regenerative activity on the progress of
AD-type neurodegeneration.
Discussion
Reduced comorbidity between Alzheimer’s disease and
cancer in the elderly
The reduced comorbidity of AD vs. cancer in the elderly
is recognized fairly lately, for less than ten years. In 2005,
Roe et al. reported prospective longitudinal data showing
a reduced risk of developing cancer among participants
with dementia of the Alzheimer-type (DAT), and a
reduced risk of developing DAT among individuals with
a history of cancer [3]. A follow-up study by this group
confirmed the inverse correlation of cancer with sporadic
AD, but not with vascular dementia, among white older
adults [4], attracting much attention in the field (see the
September issue of Neurology, 2010). In 2012, similar
findings are established in a community-based prospective
cohort study (1278 participants in total) in the United
States [5], and in a case–control study (enrolled 126 AD
patients and 252 matched controls) in Italy [6]. In 2013,
a population-based longitudinal study (enrolled 1,102
adults with a mean age of 79 years) further shows that
individuals with non-melanoma skin cancer have a
reduced risk of developing AD [10]. In a large Italy-based
cohort study (on more than 1 million Northern Italy resi-
dents), the risk of cancer in patients with AD dementia is
found to be halved, while the risk of AD dementia in
patients with cancer reduced one-third [8]. More recently,
a population-based prospective study of 2,627 people
without dementia aged 65 years and older shows that
individuals with faster cognitive decline have a decreased
risk of cancer mortality [11]. Besides western communities,
a decreased incidence of overall cancers is observed among
Chinese (with 6,960 patients enrolled) with sporadic AD
[9]. Thus, the inverse correlation of AD with cancer in the
elderly presents among different ethnic groups, and is likely
irrelevant to environmental factors.
Role of aberrant neural regenerative burden in
Alzheimer’s disease pathogenesis
The clinical phenotype of AD, largely manifested as cogni-
tive decline, is most likely a result of neurodegeneration.Cerebral atrophy is evident macroscopically in AD, and
strong evidence supports that dementia is best correlated
to neuronal/synaptic degeneration and dysfunction [12-19].
As discussed in a recent review [20], many genes regulating
cell proliferation/survival or apoptosis are altered in AD
brains, resulting in a prone-to-death state (AD phenotype).
For instances, the tumor suppressor gene p53 may be
upregulated in the brains of AD patients [20-22]. The
protein interacting with NIMA 1 (Pin1) gene, which is
overexpressed in some types of human cancers, is up-
or down-regulated in AD brains (depending on brain
region) [20,23,24]. The wingless-type murine-mammary
tumor virus integration site (Wnt) gene is important for
many developmental and adult processes, and a defect
in Wnt signaling pathway is suggested to play a role in
neurodegeneration in AD [20].
It should be noted that neural regenerative burden is
enhanced, and may be also important, in the development
of AD. Many “morphoregulatory” molecules that play
crucial role during brain development are upregulated
in the brains of AD or even prodromal AD subjects
[25-29]. These molecules are largely related to anabolic and
biosynthetic pathways mediating cell growth/differentiation,
neuritic extension, synaptic plasticity, cell adhesion, cyto-
skeleton and membrane turnover, and signaling control for
the above processes [26]. Recent microarray analyses have
clearly demonstrated prominent upregulation of numerous
genes associated with anabolic/biosynthetic cellular events
(transcription, protein biosynthesis, protein trafficking, and
turnover), mitochondrial energy generation, as well as
synaptic maintenance and function (vesicle trafficking,
neurotransmitter receptors, and synaptic structure and
stabilization), in the brains of patients with mild cogni-
tive impairment (MCI), a putative preclinical stage of
AD [18,19,28,29]. Altered expression of several nerve
growth family proteins (e.g., BDNF, TrkB and p75NTR)
has been also implicated in degenerative or regenerative
pathological events in AD, with some markers apparently
elevated in plaque-associated dystrophic neurites [30-32].
Moreover, glial activation is evident in AD brains, which
may be also viewed as a part of the rescue attempts in
response to neurodegeneration [33-36].
It is perhaps particularly worth noting that the hallmark
lesions of AD, amyloid plaques and neurofibrillary tangles,
are viewed by some as a part of host responses [27,37].
The β-amyloid precursor protein (APP) plays a trophic
role in brain development [38]. Its upregulation in AD
brain is particularly evident in dystrophic neurites around
plaques [39-42]. β-Secretase-1 (BACE1), the obligatory
enzyme initiating APP processing to β-amyloid (Aβ) pro-
duction, is also apparently elevated in plaque-associated
dystrophic axon terminals [43,44]. Further, immuno-
reactivity of presenilin-1, an active component of the
γ-secretase complex liberating Aβ products, is described
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APP, BACE1 and γ-secretase play crucial physiological
roles in neuronal and synaptic development and plasticity
[47-53]. In line with a regenerative role, the amyloidogenic
pathway is activated in response to brain injury and other
types of neuronal stress, including in wildtype animal
models and humans [36,49,54-57]. In regard to the other
principal lesion of AD, neurofibrillary tangles are caused
by intraneuronal accumulation of p-tau disassociated
from microtubules [37]. Under physiological condition,
tau binds to and stabilizes microtubules, while site-
specific phosphorylation allows its disassociation from
microtubules, which plays a physiological role in cyto-
skeleton flexibility, neuritic/synaptic plasticity and axonal
transportation [58,59]. While the mechanism and conse-
quence of abnormal tau phosphorylation in AD remains
unclear [60], p-tau proteins are richly expressed in the
brain during development [61].
While the molecular and cellular changes categorized
above as anabolic events in AD pathogenesis may be
activated to facilitate cell proliferation, survival and
regeneration to compensate neuronal death, these events
should not be generally regarded beneficial or neuronal
protective, at least not over the entire disease course.
As some of the cell surviving/regenerative responses
(e.g., inflammation, Aβ production and tau phosphoryl-
ation) eventually yield toxic/detrimental effects on neur-
onal systems, neurodegenerative changes are exacerbated
[25-27,54]. Similarly, the ectopic activation of cell cycle-
mediated events in mature neurons may end-up with
neuronal damage and death [62,63]. As a matter of fact,
the notion that maladapted regenerative responses be-
come self-propelling forces driving vicious pathological
cycles has been long proposed for AD as well as other
neurological diseases [25-27].
The AD/cancer inverse correlation would imply that
there exists a certain common biological process underlying
a “mutual-competition” for the development of either AD
or cancer. Based on this assumption, it appears that the
maladapted neural regenerative propensity in AD patho-
genesis better parallels or “matches” with the uncontrolled
proliferative propensity in cancer development (see next
section), given that cellular replication and regeneration/
repair use the same anabolic/biosynthetic machinery.
Metabolic impact of tumorogenesis on body systems
Cancer development involves complex biological deregu-
lations in cellular and tissue systems [64]. At the present,
no clear information can yet be drawn from the aforemen-
tioned epidemiological studies regarding the molecular
underpinning of the AD/cancer inverse correlation. How-
ever, the most remarkable biological feature of cancer
pathogenesis involves uncontrolled tumorous growth. We
therefore elaborate a potential impact of this change onbody systems including the brain. The anabolic activity
driving cancer development must be fueled by energy and
nutrition supply, which is available with limitation in
the body. Thus, cancer development would be associated
with a “hijack” of the body’s bioenergetic and nutritional
resources, and a deprivation thereof, from normal tissue
systems. Such an overall biological effect can be explicated
by the cachexia phenomenon in cancer patients [65].
Cachexia is suggestive of a shift of anabolic resources
to cancer tissue at the expense of catabolic activity in
other body systems. While cachexia is most evident
among end-stage cancer patients, it is reasonable to
consider that biological modulations with a deprivation
of anabolic supply by the tumorous tissue from other
cellular compartments must occur before the wasting
syndrome is overtly manifested.
As major medical attention to cancer patients is life-
saving, the extent of a potential rebalance in anabolic
kinetics between tissue compartments, especially the
effect thereof on brain metabolism and function, has
scarcely been evaluated, therefore remains unclear to
date. However, the brain receives 15-20% of the body’s
blood supply, while it weighs about 2% of the total body
mass. It is expectable that a dominated anabolic cellular
processing inherent with tumorogenesis would very likely
place a considerable or substantial deprivation effect
on the biosynthetic activity in the brain given its great
demand for and dependency on metabolic resource.
Accordingly, such an effect would likely influence the
aberrant regenerative propensity described above in
the course of AD pathogenesis.
Potential interplay between Alzheimer’s disease and
cancer pathogenesis
Having analyzed the factors relevant to AD pathogenesis
and cancer development, we propose the potential cellular
and metabolic alterations that could underlie the inverse
epidemiological association between AD and cancer
seen among the elderly (Figure 1). In the development
of AD, cell/neuronal death and surviving machineries
are activated relative to normal aging. Therefore, the
biological burden or propensity for neural degenerative
and regenerative processing is enhanced in the brain. The
degenerative events include neuronal death and synaptic
loss, which may be induced by the accumulated endo-
genous neurotoxic substances such as Aβ and p-tau. The
regenerative propensities include aberrant cell cycle acti-
vation, glial proliferation, inflammation and aberrant
neuronal sprouting, which can generate neurotoxic prod-
ucts (Aβ, inflammatory cytokines, etc.) that worsen neuro-
degeneration. As a result, a vicious pathogenic cycle of
neural degeneration and aberrant regeneration forms and
speeds up in the brain with disease progression. This






























Figure 1 Schematic illustration of a hypothetic biological model for the inverse epidemiological association between Alzheimer’s disease
(AD) and cancer in the elderly. In AD, degenerative as well as aberrant proliferative/regenerative responses are enhanced in the brain relative to
normal aging. The former manifests as neuronal death and synaptic loss, which may be caused by neurotoxic molecules (e.g., Aβ and phosphorylated
tau, inflammatory factors) overproduced in the brain. The later could be derived from maladapted regenerative changes including cell cycle reentry,
glial proliferation and aberrant neuroplasticity, which can lead to the production of the above-mentioned neurotoxic products or may directly cause
neuronal death. The vicious neuropathological cycle is maintained in the brain at the expense of body’s biosynthetic resources (energy and nutrients)
for other cellular system, which can reduce the propensity for tumorogenesis because of a mutual competition (the balance point shifting to a pro-AD
pathogenic trend). An opposite flow of the body’s biosynthetic resources occurs in the event of cancer development. The propensity of uncontrolled
cancer cell replication deprives the body’s biosynthetic resources, including that for the anabolic activity driving the aberrant regenerative burden (the
balance point shifting to pro-cancer pathogenic tendency). Consistent with the above biological mechanism, anti-cancer drugs may mitigate AD-type
neuropathology, given that their anti-proliferative pharmacological efficacy would relieve the burden of aberrant neural regeneration, and thus slows
down vicious pathogenic cycle.
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oritized blood supply to the brain (as noted in the above
paragraph), the biosynthetic resources tend to be shifted
to primarily support the AD pathogenesis, and conse-
quently, deprived from other cellular systems including
for supporting tumorogenesis. In the case of cancer devel-
opment, an opposite shift of the body’s biosynthetic
resources occurs. Thus, the uncontrolled anabolic activity
with tumorogenesis, driving by malignant genetic mod-
ulations, is capable of forming an abnormal locus that
overrides the body’s normal adjusting system for the
brain-prioritized distribution of biosynthetic resources.
This can cause a deprivation effect on anabolism in the
brain, especially the biosynthetic activities maintaining
the aberrant regenerative propensity, which may result
in a delay or slowdown of the development of AD-type
pathology (Figure 1).
The biosynthetic resource referred above as the balance
point includes the nutritional and bioenergetic systems
supporting cellular processes in general. The nutritional
components imply to substrates and catalytic elements
(e.g., vitamins and metals participating enzymatic activity)
for molecular synthesis for such as nucleotides, proteins
and lipids. Regarding bioenergetic metabolism, several
review articles have discussed this topic in relevance tothe inverse epidemiological correlation of cancer with
AD and other neurodegenerative diseases [20,66-68],
therefore we only briefly note here. Specifically, for cancer
development it has been well established that tumoro-
genesis involves a shift from oxidative phosphorylation
towards aerobic glycolysis, a phenomenon known as the
Warburg effect [69]. For AD development, it is commonly
believed that the pathologically accumulated cellular prod-
ucts (Aβ, p-tau, proinflammatory molecules) cause neur-
onal and synaptic degeneration (i.e., according to the
amyloid, tau and chronic inflammation hypotheses) [27,54].
Alternatively, AD may be considered as a metabolic disease
that is primarily caused by bioenergetic failure from the
progressive effects of aging-related damage (entropy, oxida-
tive damage, somatic mutations), with a compensatory
upregulation of energy metabolism by affected neurons,
namely an inverse Warburg effect [66,67]. It should be
noted that human imaging studies have consistently re-
vealed an overall reduced oxidative bioenergetic metabol-
ism in the brain during normal aging, and in prodromal
and definitive AD patients, especially in cerebral regions
critically involved in cognitive function [70]. Further stud-
ies would be needed to characterize the extent of inverse
Warburg effect occurring in the brains of AD subjects or
during AD-like neuropathological process, including its
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AD animal models that show typical AD type pathology
(assuming that there is a link between the metabolic
effect and neuropathology). Importantly, emerging evi-
dence suggests that the Warburg-type energy metabolism
epitomizes a physiological signature of cell proliferation
and differentiation [69,71,72]. Based on this advance in
understanding of general cell biology, one might expect
that the aberrant regenerative cellular processes described
above for AD pathogenesis, including the maladapted
neuronal and axonal regenerative attempts and glial acti-
vation [69], could be associated with a Warburg-type
energy metabolism.
In addition to the above proposed biological modifica-
tion, the use of anti-tumor drugs perhaps should be also
put into consideration, as a potential confounding factor,
especially in the interpretation of the reduced comorbidity
of AD among cancer survivors (since these patients would
have or may be continuously received anti-proliferative
treatments). In this regard, it is important to note that a
recent large population-based cohort study has shown
that the risk of developing AD, vascular dementia or other
dementias is significantly lowered in patients receiving
chemotherapy compared to those without chemotherapy,
although chemotherapy can cause drug-induced dementia
[7]. Further, in an animal study it is reported that chronic
low-dose administration of carmustine strikingly reduces
amyloid plaque burden in a mouse model of AD [73].
Moreover, some anti-cancer drugs, e.g., paclitaxel and
epothilone D, which stabilize microtubules and inhibit
mitosis, can attenuate tauopathy and axonal pathology
[74]. It is reasonable to speculate that these anti-cancer
drugs would elicit an inhibitory effect on cell proliferative
activities in the brain of the experimental animals. The
beneficial effect by cancer therapeutics seen in the AD
animal models appears in line with the notion that anti-
proliferative modulation can attenuate AD-type neuro-
pathology perhaps by relieving the regenerative burden.
In sum, these human and animal pharmacological data,
although still fairly preliminary in nature at this stage,
appear to be particularly coherent with the biological
hypothesis we put forward in this work (Figure 1).
Summary
AD has become a global healthcare crisis due to popula-
tion aging, while no promising preventive and therapeutic
strategies are currently available for this disease. The
inverse association between AD and cancer discovered
in human population-based studies deserves a great
attention in disease biology and translational research.
Additional epidemiological studies should be carried
out to further confirm this relationship, with stratified
analyses applied to determine whether this phenomenon
links to different cancer types and the use of cancer drugs.Experimental studies should start to explore how AD
conditions may influence tumorogenesis, and the cellular
and molecular mechanism thereof. Vice versa, additional
studies should be conducted to determine whether, and
if so, how, condition of cancer or anti-cancer drugs
modulate AD-type neuropathology. The concept raised
in this work may be informative for additional clinical
and explorative studies to unlock the biological basis
underlying the novel inverse correlation between AD
and cancer seen in humans. Our hypothesis has put
together multiple pieces of information (e.g., the major
neuropathological events and some genetic/molecular
modulations in AD, the Warburg-type energy metabolism
in physiological and pathological cell replication and
regeneration, and the potential effect of anti-proliferative
chemotherapy) that appear to be coherent in regard to the
mutual-competitive nature of AD vs. cancer development.
Obviously, much additional effort is needed to develop
other conceptual models in order to fully unlock the
mystery behind the AD/cancer inverse association.
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